<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810338</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0660</org_study_id>
    <nct_id>NCT04810338</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis</brief_title>
  <acronym>REMVAMIR</acronym>
  <official_title>Evaluation of the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis (Stage 5D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate in a population of chronic kidney disease patients on&#xD;
      dialysis (Stage 5D) during an observational period of 3 years:&#xD;
&#xD;
        -  the prognostic value of vascular refilling rate on mortality and on the occurrence of i)&#xD;
           cardiovascular events and ii) hospitalization number&#xD;
&#xD;
        -  the prognostic value of interdialytic weight gain on mortality and on the occurrence of&#xD;
           i) cardiovascular events and ii) hospitalization number&#xD;
&#xD;
        -  the prognostic value of perdialytic weight loss on mortality and on the occurrence of i)&#xD;
           cardiovascular events and ii) hospitalization number.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic value of vascular refilling rate on mortality</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>The refilling rate will be assessed by the ratio of relative blood volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prognostic value of vascular refilling rate on mortality</measure>
    <time_frame>3 years after inclusion</time_frame>
    <description>The refilling rate will be assessed by the ratio of relative blood volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prognostic value of vascular refilling rate on mortality</measure>
    <time_frame>3 years after inclusion</time_frame>
    <description>The refilling rate will be assessed by the ratio UF max</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prognostic value of vascular refilling rate on mortality</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>The refilling rate will be assessed by the ratio UF max</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of interdialytic weight gain</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>Prognostic value of interdialytic weight gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of interdialytic weight gain</measure>
    <time_frame>3 years after inclusion</time_frame>
    <description>Prognostic value of interdialytic weight gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of perdialytic weight loss</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>Prognostic value of perdialytic weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of perdialytic weight loss</measure>
    <time_frame>3 years after inclusion</time_frame>
    <description>Prognostic value of perdialytic weight loss</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>All patients received conventional dialysis treatment</arm_group_label>
    <description>All patients received conventional dialysis treatment during an observational period of 3 years</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients issued from dialysis units (non profit dialysis centers)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Chronic Kidney Disease patient on dialysis (stage 5D) since at least september 2017 (3&#xD;
             months prior to study start date)&#xD;
&#xD;
          -  Anuric patient&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Chronic Kidney Disease patient on dialysis with residual kidney function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul CRISTOL, Prof</last_name>
    <role>Study Director</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease patient on dialysis (stage 5D)</keyword>
  <keyword>Extracorporeal purification</keyword>
  <keyword>Sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

